Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation
journal contributionposted on 26.06.2018 by O. Shoshany, N. Abhyankar, J. Elyaguov, C. Niederberger
Any type of content formally published in an academic journal, usually following a peer-review process.
The use of pseudoephedrine, an alpha agonist, for the treatment of retrograde ejaculation is well-known, however, there is no clear consensus from the literature regarding its efficacy and treatment protocol. We evaluated the efficacy of pseudoephedrine treatment in patients with retrograde ejaculation, utilizing a yet undescribed short-period treatment protocol. Twenty men were medically treated with pseudoephedrine for retrograde ejaculation between January 2010 and May 2016 (12 with complete retrograde ejaculation and 8 with partial retrograde ejaculation). All patients had a semen analysis and post-ejaculatory urinalysis before and after treatment. The treatment protocol consisted of 60 mg of pseudoephedrine every 6 h on the day before semen analysis and two more 60 mg doses on the day of the semen analysis. Diabetes was the most common etiology for complete retrograde ejaculation (60%), whereas an idiopathic cause was the most common etiology for partial retrograde ejaculation (82%). Of the 12 complete retrograde ejaculation patients treated with pseudoephedrine prior to semen analysis, 7 (58.3%) recovered spermatozoa in the antegrade ejaculate, with a mean total sperm count of 273.5 +/- 172.5 million. Of the eight patients with partial retrograde ejaculation, five (62.5%) had a >= 50% increase in the antegrade total sperm count. In this group, the mean total sperm count increased from 26.9 +/- 8.5 million before treatment to 84.2 +/- 24.6 million after treatment, whereas the percentage of spermatozoa in the urine declined from 43.2 +/- 9% to 17 +/- 10%, respectively (both p < 0.05). Overall, in men with retrograde ejaculation treated with a pseudoephedrine regimen prior to ejaculation, some improvement in seminal parameters occurred in 14 (70%) patients, with 10 patients (38.5% of all patients) achieving antegrade total sperm counts over 39 million.